✦ LIBER ✦

Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma

✍ Scribed by Hirokazu Murakami; Kazuyuki Shimizu; Morio Sawamura; Kenshi Suzuki; Isamu Sugiura; Hiroshi Kosugi; Chihiro Shimazaki; Masafumi Taniwaki; Masahiro Abe; Toshiyuki Takagi

Book ID: 107618765
Publisher: Carden Jennings Publishing
Year: 2009
Tongue: English
Weight: 207 KB
Volume: 89
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-009-0314-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I and II pharmacokinetic and pharm

Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma

✍ Yoshiaki Ogawa; Kensei Tobinai; Michinori Ogura; Kiyoshi Ando; Takahide Tsuchiya 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB

Combined thalidomide and cyclophosphamid

Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study

✍ Sjoerd Hovenga; Simon M. G. J. Daenen; Joost T. M. de Wolf; Gustaaf W. van Imhof 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 118 KB

A systematic review of phase-II trials o

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

✍ Axel Glasmacher; Corinna Hahn; Florian Hoffmann; Ralph Naumann; Hartmut Goldschm 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB

Phase II trial of temsirolimus in patien

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

✍ Sherif S. Farag; Shuhong Zhang; Buffy S. Jansak; Xiaojing Wang; Eric Kraut; Kenn 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 508 KB

In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fat

Phase II Study of Bryostatin 1 in Patien

Phase II Study of Bryostatin 1 in Patients with Relapsed Multiple Myeloma

✍ Mary L. Varterasian; Pamela A. Pemberton; Kim Hulburd; Dorothy H. Rodriguez; Ant 📂 Article 📅 2001 🏛 Springer US 🌐 English ⚖ 42 KB

Phase 2 study of arsenic trioxide in pat

Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma

✍ Mohamad A. Hussein; Mansoor Saleh; Farhad Ravandi; James Mason; Robert M. Rifkin 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB